- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07258576
Menstruale cyclus versus orale anticonceptiva: effecten op spiereiwitmetabolisme na krachttraining (MCOC)
Het effect van de menstruatiecyclusfase en het gebruik van orale anticonceptiva op het spiereiwitmetabolisme na krachttraining
The muscles of the body are constantly breaking down old proteins and building new ones. These two processes, protein breakdown and protein synthesis, together are known as protein turnover. Protein turnover is essential for maintaining healthy muscle.
Despite its importance, females have historically been underrepresented in protein metabolism research. A long-standing assumption has been that fluctuations in female sex hormones such as estrogen and progesterone, whether across the natural menstrual cycle or in individuals using oral contraceptives (OCs), make metabolism and training responses too variable to study. Because of this, many researchers have excluded female participants for logistical reasons.
Resistance exercise, such as weightlifting, is the most effective way to increase muscle size and strength. Each resistance-training session triggers muscle protein synthesis (MPS), the process by which new muscle proteins are built. Consuming dietary protein or individual amino acids further increases the rate at which new proteins are formed. Over time, higher rates of protein synthesis support muscle growth and the maintenance of other lean tissues in the body.
The purpose of this study is to examine how menstrual cycle phases and OC use influence the synthesis of proteins in both muscle tissue and the rest of the body. Improving scientific understanding in this area will support more effective, evidence-based training and nutrition recommendations for females.
Studie Overzicht
Toestand
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Ontario
-
Toronto, Ontario, Canada, M5S 2C9
- Goldring Center for High Performance Sport
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age: 18-40 years
- BMI between 18.5-29.9 kg/m2 (non-obese)
- Recreationally active (resistance train minimum twice a week)
- Using monophasic or triphasic oral contraceptives for >1 year (for oral contraceptive users)
- Have regular menstrual cycles (21-35 days) for the past 3 months and discontinued any hormonal contraceptive use for at least 6 months (non-oral contraceptive users)
- Must meet a progesterone sufficiency test (non-oral contraceptive users)
Exclusion Criteria:
- Mid-luteal progesterone levels <16umol
- Chronic disease diagnosis (cardiovascular, thyroid, diabetes)
- Current or recent remission of cancer
- Regular use of non-steroidal anti-inflammatory drugs (NSAIDs; except low-dose aspirin), anticoagulants
- Use of prescription drugs that would impact muscle protein synthesis, e.g. Statins, Lithium, ADHD medication.
- Insertion of intrauterine device (IUD) - exception: copper
- Use of emergency contraception in the last 3 months (e.g. Plan B)
- Severe food allergies (e.g. soy, nuts)
- Smoking, use of performance enhancing drugs (growth hormones, testosterone)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Ander: Mid-Luteal Phase
5-9 days post-ovulation |
Participants will consume 16 half-hourly (8 hours) isoenergetic, isonitrogenous beverages containing 1.2 g/kg/d protein. Protein beverages will be enriched with the stable isotope [D5]phenylalanine. The use of [D5]phenylalanine will allow for determination of muscle protein synthesis. Protein beverages will be enriched with the stable isotope tracer [13C]phenylalanine. The use of [13C]phenylalanine will allow for the determination of the fate of amino acids in the body (incorporation into body protein or oxidation) which can be used to determine protein requirements. |
|
Ander: Early Follicular Phase
Days 2-6 post-menses onset |
Participants will consume 16 half-hourly (8 hours) isoenergetic, isonitrogenous beverages containing 1.2 g/kg/d protein. Protein beverages will be enriched with the stable isotope [D5]phenylalanine. The use of [D5]phenylalanine will allow for determination of muscle protein synthesis. Protein beverages will be enriched with the stable isotope tracer [13C]phenylalanine. The use of [13C]phenylalanine will allow for the determination of the fate of amino acids in the body (incorporation into body protein or oxidation) which can be used to determine protein requirements. |
|
Ander: Active Pill Phase
Days 10-20 of active pill |
Participants will consume 16 half-hourly (8 hours) isoenergetic, isonitrogenous beverages containing 1.2 g/kg/d protein. Protein beverages will be enriched with the stable isotope [D5]phenylalanine. The use of [D5]phenylalanine will allow for determination of muscle protein synthesis. Protein beverages will be enriched with the stable isotope tracer [13C]phenylalanine. The use of [13C]phenylalanine will allow for the determination of the fate of amino acids in the body (incorporation into body protein or oxidation) which can be used to determine protein requirements. |
|
Ander: Placebo Pill Phase
At least 48h after last active pill is taken |
Participants will consume 16 half-hourly (8 hours) isoenergetic, isonitrogenous beverages containing 1.2 g/kg/d protein. Protein beverages will be enriched with the stable isotope [D5]phenylalanine. The use of [D5]phenylalanine will allow for determination of muscle protein synthesis. Protein beverages will be enriched with the stable isotope tracer [13C]phenylalanine. The use of [13C]phenylalanine will allow for the determination of the fate of amino acids in the body (incorporation into body protein or oxidation) which can be used to determine protein requirements. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Muscle Protein Synthesis (MPS)
Tijdsspanne: 8 hours
|
Muscle protein synthesis (MPS) will be assessed during an 8-hour post-exercise and feeding period using a stable isotope tracer, L-[ring-D5]phenylalanine ([D5]Phe). The incorporation of the [D5]Phe tracer into myofibrillar muscle proteins, collected from muscle biopsies (pre-exercise and post-8h feeding), will be analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) to determine the fractional synthesis rate (FSR) of muscle proteins. This will help us understand how menstrual cycle phases and oral contraceptive use influence MPS, providing insight into optimizing protein intake and training adaptations in female athletes. |
8 hours
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Whole Body Protein Synthesis (WBPS)
Tijdsspanne: 4 hours
|
Whole body protein synthesis (WBPS) will be measured over a 4-hour period using the Indicator Amino Acid Oxidation (IAAO) methodology. Participants will consume a stable isotope tracer, L-[1-13C]phenylalanine ([13C]Phe), and breath samples will be collected every 30 minutes during the final 4 hours of the metabolic trial. The enrichment of 13CO₂ in breath samples will be analyzed to determine phenylalanine oxidation rates, providing an estimate of whole-body protein turnover and dietary protein utilization. This will allow us to assess whether hormonal fluctuations influence protein metabolism and nutritional requirements in female athletes. |
4 hours
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
- MCOC - REB00048059
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .